1. Home
  2. MLEC vs BCTX Comparison

MLEC vs BCTX Comparison

Compare MLEC & BCTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Moolec Science SA

MLEC

Moolec Science SA

HOLD

Current Price

$5.55

Market Cap

4.7M

Sector

Finance

ML Signal

HOLD

Logo BriaCell Therapeutics Corp.

BCTX

BriaCell Therapeutics Corp.

HOLD

Current Price

$4.20

Market Cap

28.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MLEC
BCTX
Founded
2008
2014
Country
Cayman Islands
Canada
Employees
N/A
N/A
Industry
Blank Checks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
4.7M
28.8M
IPO Year
N/A
2025

Fundamental Metrics

Financial Performance
Metric
MLEC
BCTX
Price
$5.55
$4.20
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$40.00
AVG Volume (30 Days)
25.0K
222.8K
Earning Date
04-15-2026
03-10-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$20.42
N/A
Revenue Next Year
$30.00
$380.95
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.21
$0.61
52 Week High
$23.22
$14.68

Technical Indicators

Market Signals
Indicator
MLEC
BCTX
Relative Strength Index (RSI) 35.82 49.89
Support Level $0.60 $4.10
Resistance Level $7.95 $4.51
Average True Range (ATR) 0.98 0.29
MACD -0.46 0.02
Stochastic Oscillator 8.61 55.06

Price Performance

Historical Comparison
MLEC
BCTX

About MLEC Moolec Science SA

Moolec Science SA is a science-based ingredient company focused on producing real animal proteins in plants through Molecular Farming, a technology in the alternative protein landscape. Its purpose is to upgrade the taste, nutrition, and affordability of alternative protein products while building a more sustainable and equitable food system. The company has various products in its pipeline, such as; TSP Valorasoy which is a soy protein product to produce vegetable proteins with texture and fibrousness similar to those of meat, Glaso, a safflower oil with high levels of gamma-linolenic acid, SPC2 which is a plant-based chymosin, YEEA1, an extract derived from a novel yeast biomass with specific properties, and others. The company's maximum revenues from operations in Argentina.

About BCTX BriaCell Therapeutics Corp.

BriaCell Therapeutics Corp is a clinical-stage biotechnology company focused on developing immunotherapies for cancer treatment, particularly breast cancer. The company's targeted immunotherapy program, Bria-IMT, is a targeted cell-based immunotherapy in end-stage clinical trials aiming to improve outcomes for patients with breast cancer. BriaCell also develops Bria-OTS, personalized off-the-shelf immunotherapies for breast and prostate cancer. BriaCell is involved in clinical collaborations to explore combination therapies for enhanced cancer treatment options.

Share on Social Networks: